Efficacy and Safety of AXA1665 in Cirrhotic Subjects With Prior Overt Hepatic Encephalopathy (EMMPOWER)

Axcella Health

Status and phase

Terminated

Phase 2

Conditions

Hepatic Encephalopathy

Treatments

Drug: AXA1665

Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT04816916

AXA1665-101

Details and patient eligibility

About

This is a global study to compare the effects of AXA1665, an orally active mixture of amino acids, compared to placebo, on cognitive and physical function, as well as the safety and tolerability of AXA1665.

Enrollment

12 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Willing to participate in the study and provide written informed consent.
Male and female adults aged ≥18 years.
History of cirrhosis and at least 1 prior episode of overt hepatic encephalopathy (OHE) prior to Screening.
A PHES of ≤ -4 during Screening.
MELD score of ≤ 22 at Screening.
Support of a primary caregiver who is able and willing to give written informed consent.

Exclusion criteria

Hospitalization or serious medical condition.
Presence of Child's-Pugh score ≥12, hepato-renal syndrome(s), refractory ascites, or spontaneous bacterial peritonitis (SBP).
History of a surgical portosystemic or a transjugular intrahepatic portosystemic shunt (TIPS) placement.
Expectation of a liver transplant during the study.
Use of marijuana or tetrahydrocannabinol (THC) within 1 week prior to Screening and during the study.